• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr. Michelle Melisko Discusses Access to Care for Breast Cancer Patients

Article

Dr. Michelle E. Melisko, Assistant Clinical Professor, UCSF, Helen Diller Family Comprehensive Cancer Center, explains how drug shortages are affecting patients with breast cancer and the potential impact to cost and outcomes.

doxorubicin Hcl Liposome Injection

doxorubicin),

Dr. Melisko discusses the paclitaxel (Brand name: Taxol) shortages that have impacted the ability to start patients with clinical trials. Physiscians are being asked to prescribe alternative drugs and only use Taxol when absolutely necessary. A recommended alternate to Taxol is another albumin-bound paclitaxel; however, it is costly. Doxil () has been a more serious shortage since the middle of August. Patients were able to switch to Adriamycin (which has more toxicity and side affects. However, Dr. Melisko does not feel it will necessarily impact the long-term prognosis because there are other drugs to be given. It is stressful for the patients and physicians to not be able to rely on using a specific drug.

Related Videos
Will Shapiro
Pat Van Burkleo
Jeff Stark, MD, vice president, head of medical immunology, UCB
Robert Groves, MD
Screenshot of Raajit Rampal, MD, PhD
 Laura Ferris, MD, PhD, professor of dermatology, University of Pittsburgh
Dr Padma Sripada, Columbia Internal Medicine
Screenshot of Jennifer Vaughn, MD, in a Zoom video interview
dr amy paller
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.